​AHA Services Inc, a subsidiary of the Arkansas Hospital Association (AHA), has partnered with Class Action Capital, a market leader in class action settlement claim management.

Class Action Capital is already successfully working with a very large number of hospitals, healthcare facilities, and state hospital associations across the country helping to recover meaningful refunds on their behalf from a number of recent class action settlements.
Many healthcare companies do not have the time, resources or relevant data available in order to file a settlement claim. Class Action Capital will work with you in order to submit a fully comprehensive claim recovery, while minimizing the use of your time, internal resources and the risk of mistake if you were to take on claims management on your own. ​​

Below are the latest settlement opportunities available for AHA Services, Inc. Members.

Settlement Opportunities:

Healthcare Settlements –

Lovenox Settlement – $120,000,000

This settlement alleges that Momenta Pharmaceuticals kept the prices of Lovenox and generic Enoxaparin higher than they otherwise would have been by manipulating the generic approval process that is required to ensure every batch meets FDA standards. Although Momenta did not develop Enoxaparin, it tried to use its patented processes for testing generic Enoxaparin to prevent other generic drug manufacturers from producing and selling it. Additionally, this lawsuit also claims that Momenta collaborated with Sandoz and was aware that developing a scheme to monopolize the market would lead to increased profits.

While CAC will need purchase records about Lovenox and Enoxaparin, they’ve been told by class counsel that they can use extrapolations and do not need you to submit full records from the class period.  CAC is also exploring public market research on figures about hospital size, revenue, patient care volume, etc. if you cannot provide any data.

Eligibility Requirements include hospitals, TPP, and patients without insurance who purchased, paid for, and/or reimbursed some or all of the purchase price for generic enoxaparin or Lovenox in class states between September 21, 2011 – September 30, 2015 for the purpose of personal consumption.

The deadline to file for this settlement is September 1, 2020.

Blue Cross Blue Shield National Antitrust Settlement

This settlement alleges that Blue Cross Blue Shield companies throughout the United States colluded to create territories within the US, in which only one “Blue” could sell insurance and/or contract with healthcare providers and subscribers in violation of antitrust laws. This resulted in subscribers and providers paying more than they would have in a competitive market.

Healthcare Subscribers Class

Eligibility Requirements include all persons or entities who, during the period from April 17, 2008 to the present (the “Class Period”), have paid health insurance premiums to a BCBS defendant for individual or small group full-service commercial health insurance.

Healthcare Providers Class

Eligibility Requirements include all healthcare providers, not owned or employed by a Defendant, who have provided healthcare services, equipment, or supplies in the United States at any point from 2008 through the present.

Syringe and Catheter Antitrust Settlement

This settlement alleges that healthcare providers paid higher prices for regular and safety syringes, along with safety IV catheters, given the way manufacturers and distributors led by Becton Dickinson manipulated the market. These corporations allegedly locked providers into long-term contracts with above competitive pricing and no option to use other manufacturers.

All healthcare providers in the United States who purchased Becton conventional syringes, Becton safety-IV syringes, and/or Becton safety-IV catheters on or after May 3, 2014 directly from Becton or a Becton distributor, GPO, or unnamed co-conspirator are likely eligible for compensation.

Payment Card Interchange Fee Settlement –

On September 18, 2018 an agreement was reached on behalf of all merchants who accepted VISA and/or MasterCard branded credit or debit cards between January 1, 2004 through January 25, 2019. The settlement fund will be between $5.54 – $6.24 billion depending on the number of class members who exclude themselves from the settlement. On January 24, 2019, the court preliminarily approved the new settlement and in the coming months known class members are expected to be mailed notices about their legal rights, including their right to exclude themselves from participating in this settlement. Information about the settlement will also be published in a variety of media outlets. The tentative deadline for members to exclude themselves is July 23, 2019 with a fairness hearing tentatively scheduled for November 7, 2019.

While claim forms are not available yet and potential claimants do not need to sign up with a third-party service in order to participate in any monetary relief, the difficulty may be understanding what information will be provided by the defendants, how that applies to your organization, as well as what additional information can be provided to the court administrator to ensure a complete claim. No-cost assistance will be available from the court administrator and class counsel during the claim filing period. If the Court grants the settlement final approval and any appeals are resolved, the Court will approve a claim process and establish a claim deadline. Updates about the settlement can be found on the official court authorized settlement website at: https://www.paymentcardsettlement.com


Close Bitnami banner